Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G/A | 2019-12-10 | Bank of New York Mellon Corp | TherapeuticsMD, Inc. | 13,389,805 | 4.9% | EDGAR |
SC 13G/A | 2019-09-10 | Bank of New York Mellon Corp | TherapeuticsMD, Inc. | 18,247,619 | 7.6% | EDGAR |
SC 13G/A | 2019-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | TherapeuticsMD, Inc. | 21,522,345 | 9.0% | EDGAR |
SC 13G/A | 2019-02-13 | FMR LLC | TherapeuticsMD, Inc. | 18,088,341 | 7.6% | EDGAR |
SC 13G/A | 2019-02-12 | VANGUARD GROUP INC | TherapeuticsMD, Inc. | 13,295,496 | 5.6% | EDGAR |
SC 13G/A | 2019-02-06 | BlackRock Inc. | TherapeuticsMD, Inc. | 16,687,563 | 7.0% | EDGAR |
SC 13G/A | 2019-01-29 | Bank of New York Mellon Corp | TherapeuticsMD, Inc. | 31,451,359 | 13.2% | EDGAR |
SC 13G/A | 2019-01-28 | FRANKLIN RESOURCES INC | TherapeuticsMD, Inc. | 10,543,588 | 4.4% | EDGAR |
SC 13G/A | 2019-01-28 | JPMORGAN CHASE & CO | TherapeuticsMD, Inc. | 19,836,673 | 8.3% | EDGAR |
SC 13G/A | 2018-07-10 | PRICE T ROWE ASSOCIATES INC /MD/ | TherapeuticsMD, Inc. | 23,404,309 | 10.8% | EDGAR |
SC 13G/A | 2018-06-11 | FMR LLC | TherapeuticsMD, Inc. | 11,788,053 | 5.4% | EDGAR |
SC 13D/A | 2018-04-16 | SMITH ROBERT J | TherapeuticsMD, Inc. | 9,938,708 | - | EDGAR |
SC 13D/A | 2018-02-14 | SMITH ROBERT J | TherapeuticsMD, Inc. | 12,959,108 | - | EDGAR |
SC 13G/A | 2018-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | TherapeuticsMD, Inc. | 17,431,395 | 8.0% | EDGAR |
SC 13G/A | 2018-02-13 | FMR LLC | TherapeuticsMD, Inc. | 23,068,840 | 10.7% | EDGAR |
SC 13G | 2018-02-09 | VANGUARD GROUP INC | TherapeuticsMD, Inc. | 11,403,826 | 5.3% | EDGAR |
SC 13G/A | 2018-02-07 | Bank of New York Mellon Corp | TherapeuticsMD, Inc. | 28,973,668 | 13.4% | EDGAR |
SC 13G/A | 2018-02-05 | FRANKLIN RESOURCES INC | TherapeuticsMD, Inc. | 10,992,409 | 5.1% | EDGAR |
SC 13G/A | 2018-01-26 | JPMORGAN CHASE & CO | TherapeuticsMD, Inc. | 19,648,012 | 9.0% | EDGAR |
SC 13G/A | 2018-01-23 | BlackRock Inc. | TherapeuticsMD, Inc. | 14,431,862 | 6.7% | EDGAR |